Novartis says operating profit to grow again ahead of Sandoz spin off
 
The Swiss drugmaker reported full-year core operating income was broadly flat at $16.7 billion.
Source link 
 
			 
The Swiss drugmaker reported full-year core operating income was broadly flat at $16.7 billion.
Source link